Occudo Quantitative Strategies LP Invests $648,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Occudo Quantitative Strategies LP purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,132 shares of the medical equipment provider's stock, valued at approximately $648,000.

Other large investors have also modified their holdings of the company. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at about $25,000. Accredited Wealth Management LLC purchased a new stake in Zimmer Biomet in the fourth quarter valued at approximately $36,000. Kentucky Trust Co acquired a new position in Zimmer Biomet in the 4th quarter worth approximately $39,000. OFI Invest Asset Management purchased a new position in Zimmer Biomet during the 4th quarter worth approximately $40,000. Finally, Dunhill Financial LLC lifted its stake in Zimmer Biomet by 86.6% during the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock valued at $47,000 after acquiring an additional 206 shares during the period. Hedge funds and other institutional investors own 88.89% of the company's stock.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Price Performance

NYSE:ZBH traded down $0.01 during trading hours on Tuesday, hitting $95.76. 494,399 shares of the stock were exchanged, compared to its average volume of 2,119,697. The company has a market cap of $18.95 billion, a P/E ratio of 21.52, a P/E/G ratio of 1.95 and a beta of 0.78. The firm's fifty day moving average price is $103.24 and its 200 day moving average price is $105.76. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.92 and a 52-week high of $120.13. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm's revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.94 earnings per share. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.00%. Zimmer Biomet's payout ratio is presently 21.24%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ZBH. Royal Bank of Canada reduced their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Wells Fargo & Company decreased their price objective on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Raymond James dropped their target price on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. decreased their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $113.45.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.